<p>Adoptive cell therapy (ACT) has shown remarkable success in the treatment of some malignancies, particularly leukemia. However, there are multiple factors that limit the durability of ACT in solid tumors, including dose-limiting toxicities, the immunosuppressive tumor microenvironment, and T-cell exhaustion. As the manufacture and preparation of adoptive T-cell therapies allows time and adequate conditions for ex vivo T-cell engineering, forward…
Functional genomics for improving adoptive T-cell transfer therapies
Journal for ImmunoTherapy of Cancer | | Skeate, J. G., Lee, C.-J., Stewart, C., Fischbach, M. J., Kar, B., Tsai, A. K., Kenderian, S. S., Stromnes, I. M., Largaespada, D. A., Moriarity, B. S., Rogers, L. M.
Topics: blood-cancer, immunotherapy, new-technology, research
Read the full article at Journal for ImmunoTherapy of Cancer